多发性骨髓瘤的全球造血细胞移植状况:对全球血液和骨髓移植数据库网络和全球疾病负担研究的分析

IF 4.3 Q1 Medicine Biology of Blood and Marrow Transplantation Pub Date : 2020-12-01 DOI:10.1016/j.bbmt.2020.08.018

Andrew J. Cowan , Helen Baldomero , Yoshiko Atsuta , Joseph Mikhael , Mahmoud Aljurf , Adriana Seber , Hildegard Greinix , Mickey Koh , Nina Worel , Edward N. Libby , Marcelo Pasquini , Sebastian Galeano , Wael Saber , Minako Iida , Gregorio Jaimovich , Juliana Martinez Rolon , Yoshihisa Kodera , Malek Benakli , Bazuaye G. Nosa , Alaa Elhaddad , Dietger Niederwieser

{"title":"多发性骨髓瘤的全球造血细胞移植状况:对全球血液和骨髓移植数据库网络和全球疾病负担研究的分析","authors":"Andrew J. Cowan , Helen Baldomero , Yoshiko Atsuta , Joseph Mikhael , Mahmoud Aljurf , Adriana Seber , Hildegard Greinix , Mickey Koh , Nina Worel , Edward N. Libby , Marcelo Pasquini , Sebastian Galeano , Wael Saber , Minako Iida , Gregorio Jaimovich , Juliana Martinez Rolon , Yoshihisa Kodera , Malek Benakli , Bazuaye G. Nosa , Alaa Elhaddad , Dietger Niederwieser","doi":"10.1016/j.bbmt.2020.08.018","DOIUrl":null,"url":null,"abstract":"<div>Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM.This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region.From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006.Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries.© 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.</div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2372-2377"},"PeriodicalIF":4.3000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.018","citationCount":"17","resultStr":"{\"title\":\"The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study\",\"authors\":\"Andrew J. Cowan , Helen Baldomero , Yoshiko Atsuta , Joseph Mikhael , Mahmoud Aljurf , Adriana Seber , Hildegard Greinix , Mickey Koh , Nina Worel , Edward N. Libby , Marcelo Pasquini , Sebastian Galeano , Wael Saber , Minako Iida , Gregorio Jaimovich , Juliana Martinez Rolon , Yoshihisa Kodera , Malek Benakli , Bazuaye G. Nosa , Alaa Elhaddad , Dietger Niederwieser\",\"doi\":\"10.1016/j.bbmt.2020.08.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM.This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region.From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006.Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries.© 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.</div>\",\"PeriodicalId\":9165,\"journal\":{\"name\":\"Biology of Blood and Marrow Transplantation\",\"volume\":\"26 12\",\"pages\":\"Pages 2372-2377\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.018\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biology of Blood and Marrow Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1083879120305103\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology of Blood and Marrow Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1083879120305103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 17

摘要

多发性骨髓瘤(MM)是一种浆细胞肿瘤，其特征为破坏性骨病变、贫血和肾损害。在全球范围内，获得有效治疗的机会有限。我们报告了2006-2015年全球造血细胞移植(HCT)的使用率和利用率，以更好地描述mm患者获得HCT的情况。这是对2006-2015年间每年进行的全球血液和骨髓移植网站网络回顾性调查的分析。发病率估计来自全球疾病负担研究。结果测量包括世界各地区自体和异体HCT的总数，以及新诊断的MM患者接受HCT的百分比，计算方法为历年每个地区的移植数量/每个地区MM的年总发病率。从2006年到2015年，全球MM自体HCT数量增加了107%。自体HCT的使用率在北美和欧洲地区最高，在北美从13%增加到24%，在欧洲从15%增加到22%。相比之下，非洲/地中海地区的自体HCT使用率较低，使用率仅从2006年的1.8%变化到2015年的4%。全球首例同种异体HCT治疗的数量在2012年达到高峰后，自2006年以来下降了-3%。自体HCT治疗MM的使用率在全球高收入地区有所增加，但在非洲和东地中海使用率仍然很低。需要做更多的工作来改善MM患者获得HCT的机会，特别是在低收入和中等收入国家。©2020美国移植和细胞治疗学会。Elsevier Inc.出版。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study

Multiple myeloma (MM) is a plasma cell neoplasm characterized by destructive bony lesions, anemia, and renal impairment. Access to effective therapy is limited globally. We report the rates and utilization of hematopoietic cell transplantation (HCT) globally from 2006-2015 to better characterize access to HCT for patients with MM.

This was an analysis of a retrospective survey of Worldwide Network of Blood and Marrow Transplant sites, conducted annually between 2006-2015. Incidence estimates were from the Global Burden of Disease study. Outcome measures included total number of autologous and allogeneic HCTs by world regions, and percentage of newly diagnosed MM patients who underwent HCT, calculated by the number of transplants per region in calendar year/gross annual incidence of MM per region.

From 2006 to 2015, the number of autologous HCT performed worldwide for MM increased by 107%. Utilization of autologous HCT was highest in Northern America and European regions, increasing from 13% to 24% in Northern America, and an increase from 15% to 22% in Europe. In contrast, the utilization of autologous HCT was lower in the Africa/Mediterranean region, with utilization only changing from 1.8% in 2006 to 4% in 2015. The number of first allogeneic HCT performed globally for MM declined after a peak in 2012 by -3% since 2006.

Autologous HCT utilization for MM has increased worldwide in high-income regions but remains poorly utilized in Africa and the East Mediterranean. More work is needed to improve access to HCT for MM patients, especially in low to middle income countries.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biology of Blood and Marrow Transplantation 医学-免疫学

CiteScore

6.60

自引率

0.00%

发文量

1061

审稿时长

3-6 weeks

期刊介绍： Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation.